SERMs and SERMs with estrogen for postmenopausal osteoporosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Reviews in Endocrine & Metabolic Disorders

• Publication date

  2010-05-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11154-010-9137-1PMID 20446043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging Selective Estrogen Receptor Modulators

  2012cited by this paper
• Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis

  2010cited by this paper
• Lasofoxifene in postmenopausal women with osteoporosis.

  2010influential reference
• Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

  2009cited by this paper
• Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

  2009cited by this paper
• Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.

  2009cited by this paper
• FRAX and its applications to clinical practice.

  2009cited by this paper
• Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

  2009cited by this paper
• ARZOXIFENE IN POSTMENOPAUSAL WOMEN WITH NORMAL OR LOW BONE MASS

  2009cited by this paper
• The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention.

  2008cited by this paper
• Review Article: A New Approach to Menopausal Therapy: The Tissue Selective Estrogen Complex

  2008cited by this paper
• Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings

  2008cited by this paper
• Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025

  2007cited by this paper
• Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2‐Yr Results of a Randomized, Double‐Blind, Placebo‐, and Active‐Controlled Study

  2007cited by this paper
• Estrogen-related receptors as emerging targets in cancer and metabolic disorders.

  2006cited by this paper
• What can be learned from the levormeloxifene experience?

  2006cited by this paper
• Estrogen receptors as therapeutic targets in breast cancer.

  2006cited by this paper
• Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women

  2006cited by this paper
• Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

  2006cited by this paper
• Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.

  2006cited by this paper
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cited by this paper
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes

  2006cited by this paper
• Adult Weight Change and Risk of Postmenopausal Breast Cancer

  2006influential reference
• Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

  2006cited by this paper
• Endometrial Effects of Bazedoxifene Acetate, a Novel Selective Estrogen Receptor Modulator, in Postmenopausal Women

  2005cited by this paper
• Random mandatory drugs testing of prisoners.

  2005cited by this paper
• Urogenital effects of selective estrogen receptor modulators: a systematic review

  2005cited by this paper
• Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene

  2005cited by this paper
• Safety assessment of raloxifene over eight years in a clinical trial setting*

  2005cited by this paper
• Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study

  2005cited by this paper
• Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen

  2005cited by this paper
• Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.

  2005cited by this paper
• Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

  2005cited by this paper
• Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.

  2005cited by this paper
• Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation

  2004cited by this paper
• Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

  2004cited by this paper
• Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

  2004cited by this paper
• Bone mineral density thresholds for pharmacological intervention to prevent fractures.

  2004cited by this paper
• Effect of Raloxifene on Urinary Incontinence: A Randomized Controlled Trial

  2004cited by this paper
• Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures

  2004influential reference
• Predictive Value of Low BMD for 1‐Year Fracture Outcomes Is Similar for Postmenopausal Women Ages 50‐64 and 65 and Older: Results From the National Osteoporosis Risk Assessment (NORA)

  2004cited by this paper
• A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

  2004cited by this paper
• Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

  2003cited by this paper
• The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women

  2002cited by this paper
• Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

  2002cited by this paper
• High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment.

  2002cited by this paper
• Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.

  2002cited by this paper
• The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women.

  2002cited by this paper
• Cognitive function in postmenopausal women treated with raloxifene.

  2001cited by this paper
• Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation

  2001cited by this paper
• Occurrence of stroke with tamoxifen in NSABP B-24.

  2000cited by this paper
• Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

  1999cited by this paper
• Adverse events reported by postmenopausal women in controlled trials with raloxifene.

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999influential reference
• Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.

  1999cited by this paper
• Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene.

  1999cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Effects of raloxifene hydrochloride on the endometrium of postmenopausal women.

  1997cited by this paper
• Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III

  1997influential reference
• A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women

  1996cited by this paper
• Symptoms associated with tamoxifen treatment in postmenopausal women.

  1991cited by this paper

• Steroid hormones and nephrolithiasis: regulation of urine components metabolism and inflammation

  2026cites this paper
• Identification of endoplasmic reticulum stress and mitochondrial dysfunction related biomarkers in osteoporosis

  2025cites this paper
• Liquiritin targets NF-κB/MAPK signaling to attenuate osteoclastogenesis and triggers apoptosis through PPARγ activation.

  2025cites this paper
• The novel organoselenium compound 4aa ameliorates osteoporosis by modulating gut microbiota composition and fecal metabolite profiles

  2025cites this paper
• Screening of ESR2-targeted anti-postmenopausal osteoporosis chemistry from Rehmanniae Radix Preparata based on affinity ultrafiltration with UPLC-QE-Orbitrap-MS.

  2024cites this paper
• Collagen peptides alleviate estrogen deficiency-induced osteoporosis by enhancing osteoblast differentiation and mineralization.

  2024cites this paper
• A novel shockwave-driven nanomotor composite microneedle transdermal delivery system for the localized treatment of osteoporosis: a basic science study

  2024cites this paper
• Proteomic Analysis Based on TMT Regarding the Therapeutic Action of Rhizoma Drynariae on Rats in an Osteoporosis Model

  2023cites this paper
• Based on network pharmacology and molecular docking to explore the molecular mechanism of Ginseng and Astragalus decoction against postmenopausal osteoporosis

  2023cites this paper
• Pathophysiological mechanism of acute bone loss after fracture

  2022cites this paper
• 17 β-Estradiol alleviates oxidative damage in osteoblasts by regulating miR-320/RUNX2 signaling pathway

  2021cites this paper
• The Scientific and Cultural Journey to Ovarian Rejuvenation: Background, Barriers, and Beyond the Biological Clock

  2021cites this paper
• Selective estrogen receptor modulator with estrogen does not affect the proliferation and apoptosis of uterine leiomyoma cells

  2020cites this paper
• Circadian transcription factor Dbp promotes rat calvarial osteoprogenitors osteogenic differentiation through Kiss1/GnRH/E2 signaling pathway loop

  2020cites this paper
• Enhancing Effect of Vitexin on Osteogenic Activity of Murine Pre-Osteoblastic Mc3t3-E1 Cells

  2020cites this paper
• Bone Physiology: Bone Cells, Modeling, and Remodeling

  2015cites this paper
• Effects of genistein in combination with conjugated estrogens on endometrial hyperplasia and metabolic dysfunction in ovariectomized mice.

  2015cites this paper
• Management of postmenopausal osteoporosis and the prevention of fractures.

  2014cites this paper
• Potential of Raloxifene in reversing osteoarthritis-like alterations in rat chondrocytes: An in vitro model study

  2013cites this paper
• Estrogens, Estrogen Agonists/Antagonists, and Calcitonin

  2013cites this paper
• Novel Actions of Steroid Receptors that Limit Treatment Response in Breast and Lung Cancers

  2013cites this paper
• Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate

  2013cites this paper
• Regulation of Calcium and Phosphate Metabolism

  2012cites this paper
• Prevention and treatment of osteoporosis in women: an

  2012cites this paper
• Bone Health, Osteoporosis and Fracture Risk in Neurofibromatosis 1 - An Emphasis on Osteoclasts

  2012cites this paper
• Current treatment options for vulvovaginal atrophy

  2011cites this paper
• Developmental effects related to angiogenesis and osteogenic differentiation in Salmon larvae continuously exposed to dioxin-like 3,3',4,4'-tetrachlorobiphenyl (congener 77).

  2011cites this paper